Roivant Sciences Ltd

ROIV · NASDAQ

$34.58▲ +1.90%

+$0.65 today

Mkt cap $24.40B
P/E 0.0
Day $33.56 – $34.83

Confidence

High conviction

The read

Roivant Sciences shares rose 4.6% post-earnings despite no reported EPS, supported by strong analyst buy ratings

Roivant Sciences reported Q1 2026 results without disclosed EPS, with shares gaining 4.6% on June 4. Analysts maintain a buy consensus with a $36.53 average target, reflecting confidence despite weak recent revenue trends. Institutional ownership remains high at 73%, while forward EPS growth is projected at 21.8%.

Confidence note: Analysis based on strong market reaction, analyst consensus, and institutional ownership despite missing EPS data; limited by absence of explicit guidance or reported earnings.

What happened

Earnings print

EPS was not reported; consensus estimate was -$0.38 for Q1 2026.

Guidance

No explicit guidance was provided in the report; analyst consensus remains positive with 8 buys and 1 hold.

Price reaction

Shares increased 4.6% on the earnings day, closing near $29.73, above the 50-day and 200-day SMAs.

Street narrative

Market response was positive despite lack of EPS data, supported by strong analyst buy ratings and high institutional ownership.

So what

What changed

Shares rose 4.6% post-earnings despite no EPS disclosure, supported by strong analyst buy consensus.

What the market is pricing

The 4.6% price gain and high institutional ownership reflect optimism on future EPS growth of 21.8%.

Fundamental takeaway

Maintain a neutral stance; monitor upcoming clinical or regulatory catalysts for potential upgrades.

Next 30–90 days

Bull

48%

Positive clinical trial or regulatory news drives share price above analyst targets.

Announcement of favorable clinical trial results
Regulatory approval or positive update

Base

36%

Shares trade sideways with modest volatility as market awaits clearer earnings details or catalysts.

Stable operational updates
No major news flow

Bear

16%

Emerging pipeline risks or competitive pressures lead to share price decline despite analyst optimism.

Disclosure of pipeline setbacks
Increased competitive threats

What to do

If you hold it

Hold unless upcoming clinical or regulatory updates fail to materialize within 90 days.

If you're watching

Add only if next-quarter guidance is reiterated or raised; avoid if guidance is cut or geopolitical risk escalates.

Keep on your radar

Clinical trial results or regulatory announcements within next 90 days
Share price relative to 50-day SMA (~$28.83)
Institutional ownership changes from current 73%
Analyst rating revisions or target price updates